Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GVGH iNTS GMMA vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The GVGH iNTS GMMA vaccine (iNTS-GMMA) is an investigational bivalent outer membrane vesicle-based vaccine developed by the GSK Vaccines Institute for Global Health (GVGH), a division of GSK Biologicals. It is designed to prevent invasive nontyphoidal Salmonella (iNTS) disease caused by *Salmonella enterica* serovars Typhimurium and Enteritidis. The vaccine utilizes Generalized Modules for Membrane Antigens (GMMA) — outer membrane vesicles (OMVs) shed from genetically modified *Salmonella* bacteria — as a delivery platform for the O-antigen (OAg) portion of lipopolysaccharide (LPS). The parent bacteria are genetically engineered with a `tolR` deletion to induce hyperblebbing and `msbB` and `pagP` deletions to reduce lipid A acylation, thereby lowering endotoxicity and reactogenicity. The vaccine is formulated with aluminum hydroxide (Alhydrogel) and is administered intramuscularly. It is currently in Phase II clinical development, with trials evaluating its safety, reactogenicity, and immunogenicity in African populations, including infants, children, and adults.
- Other names
- iNTS-GMMA vaccineGVGH iNTS-GMMA vaccinebivalent iNTS-GMMA vaccine
02
Targets
TLR4 (Toll-like receptor 4)Salmonella Enteritidis lipopolysaccharide O-antigenSalmonella Typhimurium lipopolysaccharide O-antigen
Beyond the preview
Go deeper on GVGH iNTS GMMA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GVGH iNTS GMMA vaccine.